The archaic practice of removing blood from the body to treat a wide range of illnesses lives on today as a standard treatment for certain blood disorders. The modern version of this approach, called therapeutic phlebotomy, can manage these conditions but still comes with limitations and complication risks. A drug from partners Protagonist Therapeutics and Takeda Pharmaceutical offers the promise of a therapeutic intervention for one of these rare blood diseases, polycythemia vera.

One-year data for the drug, rusfertide, were presented Saturday during the annual meeting of the American Society of Hematology in Orlando, Florida. Beyond showing the vast majority of study participants reached a point where they no longer needed phlebotomy, results also showed improvements on quality of lif

See Full Page